NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia - NICE TAG451

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia - NICE TAG451

Ponatinib is recommended, within its marketing authorisation, as an option for treating chronic‑, accelerated‑ or blast‑phase chronic myeloid leukaemia in adults when:

  • the disease is resistant to dasatinib or nilotinib or

  • they cannot tolerate dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate or

  • the T315I gene mutation is present.

1.2Ponatinib is recommended, within its marketing authorisation, as an option for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adults when:

  • the disease is resistant to dasatinib or

  • they cannot tolerate dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate or

  • the T315I gene mutation is present.

1.3Ponatinib is recommended only if the company provides the drug with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta451

Site by Devopa
© Copyright 2019 NHS. All rights reserved.